MedTrace Logo

Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT00552565 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 711

Last updated 2009-06-11

No results posted yet for this study

Summary

The purpose of the study is to determine the efficacy and safety of Rezular (arverapamil) in the treatment of IBS-D.

Conditions

  • Irritable Bowel Syndrome With Diarrhea

Interventions

DRUG

Rezular 15mg

Oral Tablets

DRUG

Placebo

placebo

DRUG

Rezular

Rezular 37.5mg 3xday up to 12 weeks

DRUG

Rezular

Rezular 75mg 3xday up to 12 weeks

Sponsors & Collaborators

  • AGI Therapeutics, Inc.

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00552565 on ClinicalTrials.gov